Patents Examined by Carolyn L. Smith
  • Patent number: 7034134
    Abstract: The present invention provides novel polynucleotides encoding MMP-29 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MMP-29 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: April 25, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shujian Wu, Jian Chen
  • Patent number: 6960474
    Abstract: Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: November 1, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Marco M. Gottardis, Ricardo M. Attar, Stanley R. Krystek, Jr., John S. Sack
  • Patent number: 6943240
    Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: September 13, 2005
    Assignee: Coley Pharmaceuticals GmbH
    Inventors: Stefan Bauer, Grayson Lipford, Hermann Wagner
  • Patent number: 6845328
    Abstract: The present invention is broadly directed to methods of screening ribosomal protein L11/GTPase activating region (GAR) RNA-modulating compounds by using information from the high-resolution structure of the L11/GAR complex. The methods are useful in identifying compounds useful for anti-bacterial treatments.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: January 18, 2005
    Assignee: University of Utah Research Foundation
    Inventors: Brian T. Wimberly, Venkatraman Ramakrishnan
  • Patent number: 6833447
    Abstract: The present invention relates to nucleic acid sequences from the bacterium, Myxococcus xanthus and, in particular, to genomic DNA sequences. The invention encompasses nucleic acid molecules present in non-coding regions as well as nucleic acid molecules that encode proteins and fragments of proteins. In addition, proteins and fragments of proteins so encoded and antibodies capable of binding the proteins are encompassed by the present invention. The invention also encompasses oligonucleotides including primers, e.g. useful for amplifying nucleic acid molecules, and collections of nucleic acid molecules and oligonucleotides, e.g. in microarrays. The invention also provides constructs and transgenic cells and organisms comprising nucleic acid molecules of the invention.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: December 21, 2004
    Assignee: Monsanto Technology, LLC
    Inventors: Barry S. Goldman, Gregory J. Hinkle, Steven C. Slater, Roger C. Wiegand
  • Patent number: 6826487
    Abstract: A method comprises (A) defining a first experimental space comprising factors of at least two mixtures with at least one common factor, (B) defining a second experimental space by deleting duplicate factor combinations from the first experimental space and (C) conducting an experiment on the second experimental space. A system comprises a processor that (A) defines a first experimental space comprising factors of at least two mixtures with at least one common factor and (B) defines a second experimental space by deleting duplicate factor combinations from the first experimental space. The system also comprises a reactor and evaluator to select a best case set of factors from the second experimental space by a combinatorial high throughput screening (CHTS) method to select a best case set of factors from the second experimental space.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: November 30, 2004
    Assignee: General Electric Company
    Inventors: James Norman Cawse, Ronald James Wroczynski, Darchun Billy Yang
  • Patent number: 6822082
    Abstract: The present invention provides to polynucleotides and secreted proteins encoded by the polynucleotides. The proteins include a variety of fusion proteins, including fusions comprising a signal peptide selected from the group consisting of signal peptides shown in SEQ ID NO:M, wherein M is an even integer from 2 to 328, operably linked to a second polypeptide. The invention further provides therapeutic and diagnostic methods utilizing the polynucleotides, polypeptides, and antagonists of the polypeptides.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: November 23, 2004
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell
  • Patent number: 6807492
    Abstract: An automated modeler for modeling of an interactive system comprising at least one biological entity and at least one pharmaceutical substance, the system comprising, a representation of states of said system, a knowledge tree builder, associated with said representation for allowing users to define the states, expected relationships between said states and independent inputs to the states, and a data miner associated with said representation to operate on data taken from said system to apply said data to said states in accordance with said defined relationships and inputs, thereby to apply numerical values to said relationships and said inputs, thereby to model said interactions.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: October 19, 2004
    Assignee: Insyst Ltd.
    Inventors: Avraham Oren, Yehuda Hartman, Yossi Fisher
  • Patent number: 6673549
    Abstract: The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in human C3A liver cell cultures treated with steroids or synthetic steroid analogues and which may be used entirely or in part to detect metabolic and toxicological responses to treatment with steroids and steroid antagonists, to diagnose, to stage, to treat, or to monitor the treatment of a subject with an steroid responsive disorder.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: January 6, 2004
    Assignee: Incyte Corporation
    Inventors: L. Michael Furness, Jenny L. Buchbinder
  • Patent number: 6673545
    Abstract: The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: January 6, 2004
    Assignee: Incyte Corporation
    Inventors: Mary Faris, Christopher M. Turner
  • Patent number: 6671624
    Abstract: The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: December 30, 2003
    Assignee: Cellomics, Inc.
    Inventors: R. Terry Dunlay, D. Lansing Taylor, Albert H. Gough, Kenneth A. Giuliano